asa glp-1 agonist guidelines How should we approach patients on agonists? Check out this excellent editorial from Dr. Girish Joshi, "Clarifying the and Decoding the Enigma: Strategies for Anesthetic Management of Patients on Glucagon-Like The 2023 ASA position on
Description
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
Awareness prevents these issues

The finding was replicated by tirzepatide maker Eli Lilly, who carried out tests on the impact of mixing tirzepatide and B12 and released a statement underscoring that the clinical consequences of the new molecule are not known

These are all partially correct, but none capture the full picture
